PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 5 PubMed articles · model: gemma4:31b
Summary
Background
Active compounds
Mechanism of action
Clinical evidence
Administration of Oxytropis kansuensis alkaloid fraction (OKAF) showed tumor inhibition rates of 23%, 29%, and 43% for low (8 mg/kg), moderate (16 mg/kg), and high (32 mg/kg) dosages, respectively, and increased spleen and thymus indices [PMID:20329613]
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 24148892 (2013) — The study of the Oxytropis kansuensis-induced apoptotic pathway in the cerebrum of SD rats. · BMC veterinary research
- 2.PMID: 40535712 (2025) — The complete chloroplast genome and phylogenetic analysis of Oxytropis kansuensis Bunge (Fabaceae). · Mitochondrial DNA. Part B, Resources
- 3.PMID: 24741992 (2014) — Effect of swainsonine in Oxytropis kansuensis on Golgi α-mannosidase II expression in the brain tissues of Sprague-Dawley rats. · Journal of agricultural and food chemistry
- 4.PMID: 20329613 (2009) — [In vivo anti-tumor effect of Oxytropis kansuensis alkaloid fraction and its influence on immune function]. · Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
- 5.PMID: 17126535